Cardiff Oncology Appoints Leila Alland as Interim CMO
The clinical-stage biotechnology firm names a new interim chief medical officer following the departure of Roger Sidhu.
Updated on Oct. 27, 2026 in Cancer
Cardiff Oncology announced on October 27, 2026, that Leila Alland has been appointed as the interim Chief Medical Officer. She takes over the role from Roger Sidhu, who has vacated the position.
Why it matters
The change in medical leadership comes as the San Diego-based biotechnology company prepares for upcoming clinical milestones.
Clinical trial protocols involve a 30 mg dose of onvansertib, with patients remaining on the trial for an 18-month duration. These metrics represent the current clinical-stage specifications for the company's leading oncology development program.
The players
Leila Alland
She is the newly appointed interim Chief Medical Officer of Cardiff Oncology who holds degrees from New York University and the University of Pennsylvania.
Roger Sidhu
He is the former Chief Medical Officer of Cardiff Oncology who recently vacated his position at the company.
Cardiff Oncology
This is a San Diego-based clinical-stage biotechnology company focused on developing therapies for oncology patients.
The details
The Board of Directors selected Alland, who holds a medical degree from New York University and a bachelor degree from the University of Pennsylvania, to guide the firm's medical operations. Cardiff Oncology remains focused on its clinical pipeline as it prepares for future regulatory milestones.
Timeline
Leila Alland was appointed as interim Chief Medical Officer on October 27, 2026.
The company plans to initiate a registrational Phase 3 study in the first quarter of 2027.
Health Landscape
The leadership appointment follows the trajectory of the onvansertib clinical development program. This transition aligns the firm's medical oversight with its upcoming phase of late-stage clinical research.
This leadership transition ensures that the company maintains its clinical timeline for the upcoming Phase 3 trial. Patients currently enrolled or awaiting trial inclusion will see no immediate changes to treatment protocols or study durations.
The takeaway
Management changes at clinical-stage firms often precede critical phases of trial development. Investors and patients should monitor the progress of upcoming registrational studies for updates on long-term outcomes.
What happens next
Cardiff Oncology is scheduled to initiate a registrational Phase 3 study in the first quarter of 2027.
Further reading
Learn more about local clinical research efforts in the Cancer section.
More information
For additional corporate information, visit the Cardiff Oncology official website.
Source note: This article includes information reported by Firstwordpharma.
